Momenta Pharmaceuticals, Inc. to Present M402 Preclinical Data At Upcoming American Association for Cancer Research Meeting

CAMBRIDGE, Mass., April 14, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, (formerly M-ONC 402) will be presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 18-22, 2009 in Denver, Colorado.